Could Novartis Be Gamida-Cell’s Mysterious Buyer?

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Novartis

An Israeli news source claims that Novartis AG (NYSE:NVS) is in advanced talks to buy Israeli stem-cell developer Gamida-Cell Ltd. for a rumored $600 million. The payments will be broken up into one downpayment (comprising millions of dollars) and then several hundred million dollars more for product milestones in Gamid-Cell’s research and development.

Elbit Medical Technologies, another Israeli company that currently holds a 30.8 percent stake in Gamida, says that the offer includes “significant immediate payment and additional future payments totaling hundreds of millions of dollars,” according to Reuters.

Elbit Technologies declined to comment on the Globes English report about whether Gamida’s buyer is, in fact, Swiss drugmaker Novartis AG. The offer was received on March 7, according to a statement to the Tel Aviv Stock Exchange by another Gamida shareholder, Clal Biotechnology Industries, which owns about 22 percent of Gamida.

A press release from Elbit said Tuesday that no definitive agreement has been signed and that “there is no certainty that the negotiation of such non-binding proposal will lead to the conclusion of a definitive agreement or that a transaction will be completed.”

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business